Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Bioorg Med Chem ; 26(14): 4330-4335, 2018 08 07.
Article in English | MEDLINE | ID: mdl-29716765

ABSTRACT

A modification of the Nenitzescu reaction was used to obtain Dronedarone from quinonimine 20 and 1,3-diketone 14 (R = CH2CH2CH2NBu2) in a two-stage process in almost 55% overall yield. Our results represent significant improvement over other state-of-the-art methods as no extra steps for the decoration of the benzofuran core are required.


Subject(s)
Dronedarone/chemical synthesis , Benzofurans/chemistry , Dronedarone/chemistry , Ketones/chemistry , Molecular Structure , Quinones/chemistry
2.
Future Med Chem ; 5(5): 539-51, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23573972

ABSTRACT

JNK is involved in a broad range of physiological processes. Several inflammatory and neurodegenerative diseases, such as multiple sclerosis, Alzheimer's and Parkinson's disease have been linked with the dysregulated JNK pathway. Research on disease models using the relevant knockout mice has highlighted the importance of specific JNK isoformsin-particular disorders and has stimulated further efforts in the drug-discovery area. However, most of the experimental evidence for the efficacy of JNK inhibition in animal models is from studies using JNK inhibitors, which are not isoform selective. Some of the more recent compounds exhibit good oral bioavailability, CNS penetration and selectivity against the rest of the kinome. Efforts to design isoform-selective inhibitors have produced a number of examples with various selectivity profiles. This article presents recent progress in this area and comment on the role of isoform selectivity for efficacy.


Subject(s)
Anti-Inflammatory Agents/chemistry , Anti-Inflammatory Agents/pharmacology , JNK Mitogen-Activated Protein Kinases/antagonists & inhibitors , Neuroprotective Agents/chemistry , Neuroprotective Agents/pharmacology , Protein Kinase Inhibitors/chemistry , Protein Kinase Inhibitors/pharmacology , Animals , Humans , JNK Mitogen-Activated Protein Kinases/metabolism , Protein Isoforms/antagonists & inhibitors , Protein Isoforms/metabolism
3.
J Med Chem ; 50(23): 5773-9, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17948979

ABSTRACT

A novel application of the Gini coefficient for expressing selectivity of kinase inhibitors against a panel of kinases is proposed. This has been illustrated using single-point inhibition data for 40 commercially available kinase inhibitors screened against 85 kinases. Nonselective inhibitors are characterized by Gini values close to zero (Staurosporine, Gini 0.150). Highly selective compounds exhibit Gini values close to 1 (PD184352 Gini 0.905). The relative selectivity of inhibitors does not depend on the ATP concentration.


Subject(s)
Enzyme Inhibitors/chemistry , Phosphotransferases/antagonists & inhibitors , Phosphotransferases/chemistry , Quantitative Structure-Activity Relationship , Adenosine Triphosphate/chemistry
4.
Bioorg Med Chem Lett ; 15(21): 4666-70, 2005 Nov 01.
Article in English | MEDLINE | ID: mdl-16153829

ABSTRACT

Imidazole-based structures of p38 inhibitors served as a starting point for the design of JNK3 inhibitors. Construction of a 6,7-dihydro-5H-pyrrolo[1,2-a]imidazole scaffold led to the synthesis of the (S)-enantiomers, which exhibited p38/JNK3 IC50 ratio of up to 10 and were up to 20 times more potent inhibitors of JNK3 than the relevant (R)-enantiomers. The JNK3 inhibitory potency correlated well with inhibition of c-Jun phosphorylation and neuroprotective properties of the compounds in low K+-induced cell death of rat cerebellar granule neurones.


Subject(s)
Mitogen-Activated Protein Kinase 10/antagonists & inhibitors , Protein Kinase Inhibitors/chemical synthesis , Animals , Cell Death/drug effects , Cerebellum/cytology , Imidazoles , Neurons/cytology , Neurons/drug effects , Neuroprotective Agents/chemical synthesis , Neuroprotective Agents/pharmacology , Phosphorylation , Protein Kinase Inhibitors/pharmacology , Proto-Oncogene Proteins c-jun/metabolism , Rats , Stereoisomerism , Structure-Activity Relationship , p38 Mitogen-Activated Protein Kinases/antagonists & inhibitors
5.
Prog Med Chem ; 39: 1-72, 2002.
Article in English | MEDLINE | ID: mdl-12536670

ABSTRACT

The striking efficacy of Z-VAD-fmk in the various animal models presented above may reflect its ability to inhibit multiple enzymes including caspases. In accord with this, more selective, reversible inhibitors usually show low efficacy in multifactorial models such as ischaemia, but may offer some protection against NMDA-induced excitotoxicity and hepatitis. Importantly, caspase inhibitors may exhibit significant activity in vivo even when they are applied post insult. As far as the CNS is concerned, the first systemically active inhibitors have emerged. Functional recovery could be achieved in some ischaemia models, but long-term protection by caspase inhibitors is still being questioned. Recent developments in drug design enabled the first caspase inhibitors to enter the clinic. Although initially directed towards peripheral indications such as rheumatoid arthritis, caspase inhibitors will no doubt eventually be used to target CNS disorders. For this purpose the peptidic character of current inhibitors will have to be further reduced. Small molecule, nonpeptidic caspase inhibitors, which have appeared recently, indicate that this goal can be accomplished. Unfortunately, many fundamental questions still remain to be addressed. In particular, the necessary spectrum of inhibitory activity required to achieve the desired effect needs to be determined. There is also a safety aspect associated with prolonged administration. Therefore, the next therapeutic areas for broader-range caspase inhibitors are likely to involve acute treatment. Recent results with synergistic effects between MK-801 and caspase inhibitors in ischaemia suggest that caspase inhibitors may need to be used in conjunction with other drugs. It can be expected that, in the near future, research on caspases and their inhibitors will remain a rapidly developing area of biology and medicinal chemistry. More time, however, may be needed for the first caspase inhibitors to appear on the market.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/drug effects , Caspase Inhibitors , Cysteine Proteinase Inhibitors/pharmacology , Animals , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Caspases/physiology , Cysteine Proteinase Inhibitors/chemistry , Drug Design , Humans , Inflammation/drug therapy , Structure-Activity Relationship
6.
Restor Neurol Neurosci ; 14(1): 1-23, 1999.
Article in English | MEDLINE | ID: mdl-12671267

ABSTRACT

Contribution of apoptotic mechanisms to neurodegeneration is an emerging concept. Caspases which are activated during apoptotic cell death may serve as an attractive target of pharmacological intervention. Caspase inhibitors include proteins, peptides, peptidomimetics and various small molecules. Peptide conjugates with quinones, epoxyquinones and epoxyquinols which constitute new types of pharmaeophores exhibit submicromolar activity against caspase-3 and show moderate neuroprotective effects on neuronal cells. Peptide-derived inhibitors may suffer from insufficient cell membrane permeability. However, double ester-type prodrugs may offer an option to transport a peptide-like inhibitor across the cell membrane. These developments may lead to identification of novel neuroprotective drugs.

7.
J Org Chem ; 61(9): 2995-3002, 1996 May 03.
Article in English | MEDLINE | ID: mdl-11667160

ABSTRACT

Both C(2)-P bond breaking and formation in the S-C-P(+) system do not occur according to the antiperiplanar lone pair hypothesis. Experiments using 2-phosphonio derivatives of 5-tert-butyl-1,3-dithiane and cis-4,6-dimethyl-1,3-dithiane are against the participation of higher-energy boat conformers as reactive intermediates. The results obtained support a possibility of conformational adjustment in the course of the reaction. Stereoelectronic control of the C(2)-P bond breaking and formation results from interplay of several factors. The role of the n(S)-sigma(C(2))(-)(P) and sigma(C(4,6))(-)(S)-sigma(C(2))(-)(P) hyperconjugation, as well as of the repulsive interactions between lone electron pairs pi(S) of endocyclic sulfur atoms and pi-electrons of the phenyl ring(s) connected with phosphorus, is discussed.

SELECTION OF CITATIONS
SEARCH DETAIL
...